Literature DB >> 3293683

pA2 values for antagonists of platelet activating factor on aggregation of rabbit platelets.

S R O'Donnell1, C J Barnett.   

Abstract

1. The relative potencies, and equilibrium dissociation constants, for nine antagonists of platelet activating factor (Paf) have been determined on rabbit platelets (in diluted platelet-rich plasma (PRP)) in experiments in which the aggregatory response to Paf was measured. 2. Log concentration-response (% maximum) curves to Paf were obtained in the absence (controls) and presence of different concentrations of each Paf antagonist drug. The antagonists shifted the Paf curves to a higher concentration range and the slopes of the Schild plots, constructed from these data, suggested that the drugs were competitive antagonists of Paf. The slopes of the Schild plots for CV-3988 and SRI 63-119 were greater than 1. 3. The pA2 values (pKB values in parentheses) were: WEB 2086 7.31 (7.63); SRI 63-119 6.95; L-652,731 6.71 (6.73); BN 52021 6.38 (6.47); SRI 63-072 6.36 (6.43); CV-3988 5.87; 48740 RP 4.97 (5.07); ketotifen 4.94 (4.95); thiazinamium 4.73 (4.76). 4. This study provides, for the first time, some functional response data for Paf antagonists (pKB values) which are in an appropriate form for use in classifying putative Paf receptors. The study also provides the comparative potencies of these Paf antagonists in inhibiting Paf-induced platelet aggregation. WEB 2086 was the most potent of the drugs examined.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293683      PMCID: PMC1853981          DOI: 10.1111/j.1476-5381.1988.tb11545.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

Review 1.  Platelet-activating factor antagonists.

Authors:  R N Saunders; D A Handley
Journal:  Annu Rev Pharmacol Toxicol       Date:  1987       Impact factor: 13.820

2.  The effects on Schild regressions of antagonist removal from the receptor compartment by a saturable process.

Authors:  T P Kenakin; D Beek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-02       Impact factor: 3.000

Review 3.  Perspectives in platelet-activating factor research.

Authors:  P Braquet; L Touqui; T Y Shen; B B Vargaftig
Journal:  Pharmacol Rev       Date:  1987-06       Impact factor: 25.468

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Inhibition by a stable analogue of adenosine triphosphate of platelet aggregation by adenosine diphosphate.

Authors:  G V Born; J G Foulks
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

6.  Species difference in the specific receptors of platelet activating factor.

Authors:  S B Hwang; M H Lam
Journal:  Biochem Pharmacol       Date:  1986-12-15       Impact factor: 5.858

7.  Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes.

Authors:  G Lambrecht; M J Parnham
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

8.  LG 30435, a new bronchodilator/antiallergic agent, inhibits PAF-acether induced platelet aggregation and bronchoconstriction.

Authors:  M Criscuoli; A Subissi; L Daffonchio; C Omini
Journal:  Agents Actions       Date:  1986-11

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  CV-3988 - a specific antagonist of platelet activating factor (PAF).

Authors:  Z Terashita; S Tsushima; Y Yoshioka; H Nomura; Y Inada; K Nishikawa
Journal:  Life Sci       Date:  1983-04-25       Impact factor: 5.037

View more
  12 in total

1.  Effects of PAF and PAF antagonists on the shape of venous endothelial cells in vitro.

Authors:  A M Northover
Journal:  Agents Actions       Date:  1989-08

2.  Antagonism of platelet activating factor-induced chemiluminescence in guinea-pig peritoneal macrophages in differing states of activation.

Authors:  M J Parnham; C Bittner; G Lambrecht
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

Review 3.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

4.  Influence of plasma protein content and platelet number on the potency of PAF and its antagonist RP 59227 in rabbit platelet preparations.

Authors:  A Floch; I Cavero
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

5.  Stimulation of sodium pump by vasoactive intestinal peptide in guinea-pig isolated trachea: potential contribution to mechanisms underlying relaxation of smooth muscle.

Authors:  K J Morrison; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 6.  Thieno-triazolo-1,4-diazepines as antagonists of platelet-activating factor: present status.

Authors:  J Casals-Stenzel
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.

Authors:  T Yamada; M Saito; T Mase; H Hara; H Nagaoka; K Murase; K Tomioka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

8.  Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury.

Authors:  Rebecca C Garland; Dawei Sun; Souska Zandi; Fang Xie; Sepideh Faez; Faryan Tayyari; Sonja A F Frimmel; Alexander Schering; Shintaro Nakao; Ali Hafezi-Moghadam
Journal:  FASEB J       Date:  2011-01-21       Impact factor: 5.191

9.  Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor.

Authors:  H Bohn; J Brendel; P A Martorana; K Schönafinger
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

10.  Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation.

Authors:  D Tsoukatos; C A Demopoulos; A D Tselepis; M C Moschidis; A Donos; A Evangelou; J Benveniste
Journal:  Lipids       Date:  1993-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.